Anthony M. Lynch

Mutagenic and carcinogenic potency determinations for NDMA support the cumulative dose assumption underpinning the less-than-lifetime Threshold of Toxicological Concern

The paper applies BMD modeling to NDMA datasets to support the cumulative dose assumption in the LTL-TTC framework, showing short-term assays can predict long-term carcinogenicity.

Alignment between Duplex Sequencing and transgenic rodent mutation assay data in the assessment of in vivo NDMA-induced mutagenesis

This study aligns Duplex Sequencing with transgenic rodent mutation assay data to assess in vivo NDMA-induced mutagenesis, finding dose-dependent mutation frequency increases and concordant benchmark dose estimates.